![Patrick Crutcher](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrick Crutcher
Plus aucun poste en cours
Fortune : 11 M $ au 30/06/2026
Profil
Patrick J.
Crutcher is Chief Executive Officer at Mach5 Therapeutics, Inc. and Independent Director at Amanat Acquisition Corp.
Former roles include President & Chief Executive Officer at AlmataBio, Inc., Chairman & President at Ichorion Therapeutics, Inc. from 2017 to 2018, and Chief Strategy Officer at Avalo Therapeutics, Inc. in 2019.
Education includes graduate studies at the University of California, Los Angeles and undergraduate studies at the University of Illinois.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 06/08/2025 | 549 467 ( 1,04% ) | 10 M $ | 30/06/2026 | |
iBio, Inc.
 iBio, Inc. Pharmaceuticals: OtherHealth Technology Engages in the development and commercialization of vaccines and therapeutic proteins 0,87% | 30/06/2025 | 300 438 ( 0,87% ) | 525 767 $ | 30/06/2026 |
1,15% | 20/05/2026 | 25 000 ( 1,15% ) | 254 000 $ | 30/06/2026 |
Jasper Therapeutics, Inc.
 Jasper Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company which engages in enabling cures through hematopoietic stem cell therapy 1,85% | 16/07/2026 | 518 331 ( 1,85% ) | 218 217 $ | 30/06/2026 |
Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company which engages in enabling cures through hematopoietic stem cell therapy 9,98% | 20/07/2026 | 463 452 ( 9,98% ) | 195 113 $ | 30/06/2026 |
Postes actifs de Patrick Crutcher
| Sociétés | Poste | Début |
|---|
Anciens postes connus de Patrick Crutcher
| Sociétés | Poste | Fin |
|---|---|---|
| AVALO THERAPEUTICS, INC. | Corporate Officer/Principal | 01/11/2019 |
Ichorion Therapeutics, Inc.
 Ichorion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceutical products | Directeur Général | 01/09/2018 |
Formation de Patrick Crutcher
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
3
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
University of California, Los Angeles
 University of California, Los Angeles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Illinois
 University of Illinois Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Avalo Therapeutics, Inc.
 Avalo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics for patients with unmet clinical need in immunology and rare genetic diseases | Health Technology |
Ichorion Therapeutics, Inc.
Ichorion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceutical products | Health Technology |
